EIF4A1 and diffuse large B-cell lymphoma: Altogether, the above clinical data endorses the claim that higher eIF4A1 gene expression is associated with poor survival and more aggressive clinicopathological features, supporting our notion that eIF4A1 is a promising therapeutic target in DLBCL.